10-Q · May 14, 2026
Edesa Biotech's Q2 2026 report highlighted a notable increase in net losses, reporting $4.2 million or $0.49 per share, compared to a $1.6 million loss and $0.30 per share in Q2 2025. Operating expenses rose…
Earnings analysis · 10-Q
EDSA earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The extracted 10-Q sections do not provide the income statement, balance sheet, cash-flow statement or segment disclosures, so current-period revenue, margins, EPS, cash flow and working-capital trends cannot be…
Read full summary
The extracted 10-Q sections do not provide the income statement, balance sheet, cash-flow statement or segment disclosures, so current-period revenue, margins, EPS, cash flow and working-capital trends cannot be quantified from the supplied filing text. Management reported effective disclosure controls as of June 30, 2026 and no material internal-control changes during the quarter. No material risk-factor changes or quantitative financial guidance were disclosed.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure controls remained effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, with the evaluation performed under the supervision of the CEO and CFO.
-
No material control changes
The filing reports no changes during the quarter ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
-
Recent financing and equity-plan actions
The company disclosed Amendment No. 5 to its 2019 Equity Incentive Compensation Plan and included purchase and registration-rights agreements dated June 10, 2026 among the exhibits.
What to watch
-
Existing liquidity risks remain
The company states that there have been no material changes to the risk factors in its September 30, 2025 Form 10-K, filed December 12, 2025; therefore, the existing clinical, financing and liquidity risks remain applicable.
Management's outlook
No quantitative revenue or EPS guidance was provided in the 10-Q. The filing states that the company is a smaller reporting company and is not required to provide market-risk disclosures under Item 3.
Earlier filings 4
10-Q · February 13, 2026
Edesa reported a Q1 (three months ended December 31, 2025) net loss of $2,247,669 (loss per share $0.28) versus a net loss of $1,617,253 (loss per share $0.48) in the prior-year quarter, with cash increasing to…
10-K · December 12, 2025
Edesa reported positive Phase 3 results for paridiprubart (EB05) showing statistically significant 28-day mortality 39% vs 52% (absolute improvement 13%; p<0.001) and 60-day mortality 46% vs 59% (absolute improvement…
10-K · December 13, 2024
Edesa is a pre-revenue, clinical-stage biotech focused on immuno-inflammatory diseases (Medical Dermatology and Respiratory). Fiscal 2024 showed expense reductions and an improved net loss of $6.2 million (loss per…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.